Substrates, inhibitors and activators of P-glycoprotein: Candidates for radiolabeling and imaging perspectives

Current Topics in Medicinal Chemistry

Volumn 10, Issue 17, 2010, Pages 1703-1714

  Colabufo, Nicola A ^a   Berardi, Francesco ^a   Perrone, Maria Grazia ^a   Capparelli, Elena ^a   Cantore, Mariangela ^a   Inglese, Carmela ^a   Perrone, Roberto ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Expression; Function; Inducer; Inhibitor; Modulator; P glycoprotein; PET; Substrate

Indexed keywords

CARBON 11; CYCLOSPORIN A; DOXORUBICIN; ELACRIDAR; ELACRIDAR C 11; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; LANIQUIDAR; LANIQUIDAR C 11; LOPERAMIDE; LOPERAMIDE C 11; MC 18; MC 18 C 11; MC 266; MC 266 C 11; MC 80; MC 80 C 11; N NORLOPERAMIDE; RHODAMINE 123; TARIQUIDAR C 11; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VERAPAMIL C 11;

ARTICLE; ASSAY; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; HUMAN; IC 50; IMAGING; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; TECHNIQUE;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; ISOTOPE LABELING; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY;

EID: 77958004738     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610792928022     Document Type: Article

References (54)

1. Colabufo, N. A.; Berardi, F.; Contino, M.; Niso, M.; Perrone, R. ABC pumps and their role in active drug transport. Curr. Top. Med. Chem., 2009, 9, 119-129.
2. Staud, F.; Ceckova, M.; Micuda, S.; Pavek, P. Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol. Biol., 2010, 596, 199-222.
3. Ohtsuki, S.; Terasaki, T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res., 2007, 24, 1745-1758.
4. Pérez-Tomás, R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem., 2006, 13, 1859-1876.
5. Lazarowski, A.; Czornyj, L.; Lubienieki, F.; Girardi, E.; Vazquez, S.; D'Giano, C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia, 2007, 48, 140-149.
6. Urquhart, B. L.; Kim, R. B. Blood-brain barrier transporters and response to CNS-active drugs. Eur. J. Clin. Pharmacol., 2009, 65, 1063-1070.
7. Lee, G.; Bendayan, R. Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm. Res., 2004, 21, 1313-1330.
8. Vogelgesang, S.; Cascorbi, I.; Schroeder, E.; Pahnke, J.; Kroemer, H. K.; Siegmund, W.; Kunert-Keil, C.; Walker, L. C.; Warzok, R. W. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly nondemented humans. Pharmacogenetics, 2002, 12, 535-541.
9. Kortekaas, R.; Leenders, K. L.; van Oostrom, J. C.; Vaalburg, W.; Bart, J.; Willemsen, A. T.; Hendrikse, N. H. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol., 2005, 57, 176-179.
10. Rapposelli, S.; Digiacomo, M.; Balsamo, A. P-gp transporter and its role in neurodegenerative diseases. Curr. Top. Med. Chem., 2009, 9, 209-217.
11. Kooij, G.; van Horssen, J.; de Lange, E. C.; Reijerkerk, A.; van der Pol, S. M.; van Het Hof, B.; Drexhage, J.; Vennegoor, A.; Killestein, J.; Scheffer, G.; Oerlemans, R.; Scheper, R.; van der Valk, P.; Dijkstra, C. D.; de Vries, H E. T lymphocytes impair Pglycoprotein function during neuroinflammation. J. Autoimmun., 2010, 34, 416-425.
12. Syvänen, S.; Hooker, A.; Rahman, O.; Wilking, H.; Blomquist, G.; Långström, B.; Bergström, M.; Hammarlund-Udenaes, M. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J. Pharm. Sci., 2008, 97, 5386-5400.
13. 11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl. Med. Biol., 2003, 30, 747-751.
14. 11C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. J. Nucl. Med., 2006, 47, 1531-1537.
15. Colabufo, N. A.; Berardi, F.; Cantore, M.; Contino, M.; Inglese, C.; Niso, M.; Perrone, R. Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials. J. Med. Chem., 2010, 53, 1883-1897.
16. 11Cloperamide and its N-desmethyl radiometabolite are avid substrates for brain permeability-glycoprotein efflux. J. Nucl. Med., 2008, 49, 649-656.
17. 11C-colchicine for PET imaging of multiple drug resistance. J. Nucl. Med., 2000, 41, 493-501.
18. Doze, P.; Elsinga, P. H.; Maas, B.; Van Waarde, A.; Wegman, T.; Vaalburg, W. Synthesis and evaluation of radiolabeled antagonists for imaging of beta-adrenoceptors in the brain with PET. Neurochem. Int., 2002, 40, 145-155.
19. Lewis, J. S.; Dearling, J. L.; Sosabowski, J. K.; Zweit, J.; Carnochan, P.; Kelland, L. R.; Coley, H. M.; Blower, P. J. Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET. Eur. J. Nucl. Med., 2000, 27, 638-646.
20. Sharma, V.; Beatty, A.; Wey, S. P.; Dahlheimer, J.; Pica, C. M.; Crankshaw, C. L.; Bass, L.; Green, M. A.; Welch, M. J.; Piwnica-Worms, D. Novel gallium(III) complexes transported by MDR1 P-glycoprotein: potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo. Chem. Biol., 2000, 7, 335-343.
21. Piwnica-Worms, D.; Kesarwala, A. H.; Pichler, A.; Prior, J. L.; Sharma, V. Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant P-glycoprotein-monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease. Neuroimaging Clin. N. Am., 2006, 16, 575-589.
22. 11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J. Med. Chem., 2009, 52, 6073-6082.
23. 11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl. Med. Biol., 2009, 36, 643-649.
24. 11C]Tariquidar. EANM, 2009, OP339.
25. Kannan, P.; John, C.; Zoghbi, S. S.; Halldin, C.; Gottesman, M. M.; Innis, R. B.; Hall, M. D. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin. Pharmacol. Ther., 2009, 86, 368-377.
26. 11C]verapamil kinetics in human tissues. Eur. J. Clin. Pharmacol., 2001, 56, 827-829.
27. Sasongko, L.; Link, J. M.; Muzi, M.; Mankoff, D. A.; Yang, X.; Collier, A. C.; Shoner, S. C.; Unadkat, J. D. Imaging P-glycoprotein transport activity at the human blood brain barrier with positron emission tomography. Clin. Pharmacol. Ther., 2005, 77, 503-514.
28. Pauli-Magnus, C.; von Richter, O.; Burk, O.; Ziegler, A.; Mettang, T.; Eichelbaum, M.; Fromm, M. F. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J. Pharmacol. Exp. Ther., 2000, 293, 376-382.
29. 11C]verapamil measured with PET. Neuroimage, 2003, 20, 1775-1782.
30. 11C-verapamil in the brain: studies of healthy humans. J. Nucl. Med., 2009, 50, 1267-1275.
31. 11C-verapamil and PET. J. Nucl. Med., 2008, 49, 1328-1335.
32. 11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J. Med. Chem., 2008, 51, 6034-6043.
33. 11C-N-desmethylloperamide in monkeys. J. Nucl. Med., 2009, 50, 108-115.
34. 11C-N-desmethylloperamide, a PET radiotracer to measure the function of Pglycoprotein. J. Nucl. Med., 2009, 50, 807-813.
35. Hyafil, F.; Vergely, C.; Du Vignaud, P.; Grand-Perret, T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res., 1993, 53, 4595-4602.
36. Mandema, J. W.; Gubbens-Stibbe, J. M.; Danhof, M. Stability and pharmacokinetics of flumazenil in the rat. Psychopharmacology, (Berl) 1991, 103, 384-387.
37. Shao, X.; Lisi, J. M.; Butch, E. R.; Kilbourn, M. R.; Snyder, S. E. N-Methylpiperidinemethyl, N-methylpyrrolidyl and N-methylpyrroli-dinemethyl esters as PET radiotracers for acetylcholinesterase activity. Nucl. Med. Biol., 2003, 30, 293-302.
38. Wang, R. B.; Kuo, C. L.; Lien, L. L.; Lien, E. J. Structure-activity relationship: analyses of P-glycoprotein substrates and inhibitors. J. Clin. Pharm. Ther., 2003, 28, 203-228.
39. Stewart, A. J.; Mistry, P.; Dangerfield, W.; Bootle, D.; Baker, M.; Kofler, B.; Okiji, S.; Baguley, B. C.; Denny, W. A.; Charlton, P. A. Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs, 2001, 12, 359-367.
40. Martin, C.; Berridge, G.; Mistry, P.; Higgins, C.; Charlton, P.; Callaghan, R. Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry, 2000, 39, 11901-11906.
41. Martin, C.; Berridge, G.; Higgins, C. F.; Mistry, P.; Charlton, P.; Callaghan, R. Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol., 2000, 58, 624-632.
42. Ishiwata, K.; Kawamura, K.; Yanai, K.; Hendrikse, N. H. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J. Nucl. Med., 2007, 48, 81-87.
43. Syvänen, S.; Blomquist, G.; Sprycha, M.; Höglund, A. U.; Roman, M.; Eriksson, O.; Hammarlund-Udenaes, M.; Långström, B.; Bergström, M. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage, 2006, 32, 1134-1141.
44. Syvänen, S.; Hooker, A.; Rahman, O.; Wilking, H.; Blomquist, G.; Långström, B.; Bergström, M.; Hammarlund-Udenaes, M. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J. Pharm. Sci., 2008, 97, 5386-5400.
45. Van Waarde, A.; Ramakrishnan, N. K; Rybczynska, A. A.; Elsinga, P. H.; Berardi, F.; de Jong, J. R.; Kwizera, C.; Perrone, R.; Cantore, M.; Sijbesma, J. W. A.; Dierckx, R. A.; Colabufo, N. A. Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression. J. Med. Chem., 2009, 52, 4524-4532.
46. 11C] labelled tracer for imaging P-gp. Bioorg. Med. Chem. manuscript submitted.
47. Colabufo, N. A.; Berardi, F., Cantore, M.; Perrone, M. G.; Contino, M.; Inglese, C.; Niso, M.; Perrone, R.; Azzariti, A.; Simone, les: SAR studies on tetrahydroisoquinoline derivatives. Bioorg. Med. Chem., 2008, 16, 362-373.
48. Colabufo, N. A.; Berardi, F.; Cantore, M.; Perrone, M. G.; Contino, M.; Inglese, C.; Niso, M.; Perrone, R.; Azzariti, A.; Simone, G. M.; Paradiso, A. 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxy-tetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg. Med. Chem., 2008, 16, 3732-3743.
49. Sharom, F. J.; Siarheyeva, A. In: Functional Assays for Identification of Compounds that Interact with P-gp. Multidrug Resistance: Biological and Pharmaceutical Advance in the Antitumour Treatment; Colabufo, N. A. Ed.; Research Signpost: Kerala (India), 2008, 261-290.
50. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.; Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. S. Rational use of in vitro P-glycoprotein assays in drug discovery. Pharmacol. Exp. Ther., 2001, 299, 620-628.
51. Feng, B.; Mills, J. B.; Davidson, R. E.; Mireles, R. J.; Janiszewski, J. S.; Troutman, M. D.; de Morais, S. M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos., 2008, 36, 268-275.
52. Arellano, C.; Philibert, C.; Vachoux, C.; Woodley, J.; Houin, G. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs. J. Pharm. Pharm. Sci., 2007, 10, 26-36.
53. Berruet, N.; Sentenac, S.; Auchere, D.; Gimenez, F.; Farinotti, R.; Fernandez, C. Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats. J. Pharm. Pharm. Sci., 2005, 8, 226-234.
54. Benet, L. Z.; Cummins, C. L.; Wu, C. Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm., 2004, 277, 3-9.